Dermatological Disorders in Parkinson's Disease

Robert B. Skinner, Mark Ledoux

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The first suggestion of an increased risk of melanoma in Parkinson disease (PD) patients was reported by Skibba et al. (Arch Pathol 93:556-561, 1972) in 1972. They reported a 55-year-old male with PD who developed a local recurrence of a primary melanoma and multiple primary melanomas 4 years after primary excision and 4 months after starting levodopa. Since levodopa is a metabolite in the biosynthesis of dopamine and melanin involving the enzyme tyrosinase, and increased tyrosinase activity is found in melanoma, they speculated that levodopa "could enhance and stimulate growth on any residual melanoma tissue".

Original languageEnglish (US)
Title of host publicationParkinson's Disease and Nonmotor Dysfunction
PublisherSpringer Basel
Pages237-242
Number of pages6
ISBN (Print)9781607614289
DOIs
StatePublished - Jan 1 2013

Publication series

NameMilestones in Drug Therapy
Volume24
ISSN (Print)2296-6056

Fingerprint

Parkinson Disease
Melanoma
Levodopa
Monophenol Monooxygenase
Recurrence
Enzymes
Growth

All Science Journal Classification (ASJC) codes

  • Drug Discovery
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Skinner, R. B., & Ledoux, M. (2013). Dermatological Disorders in Parkinson's Disease. In Parkinson's Disease and Nonmotor Dysfunction (pp. 237-242). (Milestones in Drug Therapy; Vol. 24). Springer Basel. https://doi.org/10.1007/978-1-60761-429-6_16

Dermatological Disorders in Parkinson's Disease. / Skinner, Robert B.; Ledoux, Mark.

Parkinson's Disease and Nonmotor Dysfunction. Springer Basel, 2013. p. 237-242 (Milestones in Drug Therapy; Vol. 24).

Research output: Chapter in Book/Report/Conference proceedingChapter

Skinner, RB & Ledoux, M 2013, Dermatological Disorders in Parkinson's Disease. in Parkinson's Disease and Nonmotor Dysfunction. Milestones in Drug Therapy, vol. 24, Springer Basel, pp. 237-242. https://doi.org/10.1007/978-1-60761-429-6_16
Skinner RB, Ledoux M. Dermatological Disorders in Parkinson's Disease. In Parkinson's Disease and Nonmotor Dysfunction. Springer Basel. 2013. p. 237-242. (Milestones in Drug Therapy). https://doi.org/10.1007/978-1-60761-429-6_16
Skinner, Robert B. ; Ledoux, Mark. / Dermatological Disorders in Parkinson's Disease. Parkinson's Disease and Nonmotor Dysfunction. Springer Basel, 2013. pp. 237-242 (Milestones in Drug Therapy).
@inbook{bf49d95eaf114da3b242ac9543003883,
title = "Dermatological Disorders in Parkinson's Disease",
abstract = "The first suggestion of an increased risk of melanoma in Parkinson disease (PD) patients was reported by Skibba et al. (Arch Pathol 93:556-561, 1972) in 1972. They reported a 55-year-old male with PD who developed a local recurrence of a primary melanoma and multiple primary melanomas 4 years after primary excision and 4 months after starting levodopa. Since levodopa is a metabolite in the biosynthesis of dopamine and melanin involving the enzyme tyrosinase, and increased tyrosinase activity is found in melanoma, they speculated that levodopa {"}could enhance and stimulate growth on any residual melanoma tissue{"}.",
author = "Skinner, {Robert B.} and Mark Ledoux",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/978-1-60761-429-6_16",
language = "English (US)",
isbn = "9781607614289",
series = "Milestones in Drug Therapy",
publisher = "Springer Basel",
pages = "237--242",
booktitle = "Parkinson's Disease and Nonmotor Dysfunction",

}

TY - CHAP

T1 - Dermatological Disorders in Parkinson's Disease

AU - Skinner, Robert B.

AU - Ledoux, Mark

PY - 2013/1/1

Y1 - 2013/1/1

N2 - The first suggestion of an increased risk of melanoma in Parkinson disease (PD) patients was reported by Skibba et al. (Arch Pathol 93:556-561, 1972) in 1972. They reported a 55-year-old male with PD who developed a local recurrence of a primary melanoma and multiple primary melanomas 4 years after primary excision and 4 months after starting levodopa. Since levodopa is a metabolite in the biosynthesis of dopamine and melanin involving the enzyme tyrosinase, and increased tyrosinase activity is found in melanoma, they speculated that levodopa "could enhance and stimulate growth on any residual melanoma tissue".

AB - The first suggestion of an increased risk of melanoma in Parkinson disease (PD) patients was reported by Skibba et al. (Arch Pathol 93:556-561, 1972) in 1972. They reported a 55-year-old male with PD who developed a local recurrence of a primary melanoma and multiple primary melanomas 4 years after primary excision and 4 months after starting levodopa. Since levodopa is a metabolite in the biosynthesis of dopamine and melanin involving the enzyme tyrosinase, and increased tyrosinase activity is found in melanoma, they speculated that levodopa "could enhance and stimulate growth on any residual melanoma tissue".

UR - http://www.scopus.com/inward/record.url?scp=84899437036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899437036&partnerID=8YFLogxK

U2 - 10.1007/978-1-60761-429-6_16

DO - 10.1007/978-1-60761-429-6_16

M3 - Chapter

SN - 9781607614289

T3 - Milestones in Drug Therapy

SP - 237

EP - 242

BT - Parkinson's Disease and Nonmotor Dysfunction

PB - Springer Basel

ER -